Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most ...

Retatrutide, a new experimental weight-loss drug, targets three hormones and shows promising results far beyond current ...

A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...

Retatrutide targets three key pathways linked to appetite, metabolism, and energy use: GLP-1, GIP, and glucagon. GLP-1 and ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called ...

Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 TRIUMPH-4 clinical trial ...

A weight loss drug dubbed the "triple G" drug for its effectiveness in mimicking three hunger-regulating hormones showed promising results in new data released Thursday by its maker, Eli Lilly.